[HTML][HTML] Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): An …

…, E Gray, A Scott, M Baxter, A Mullard… - The lancet …, 2023 - thelancet.com
Background Temporary drug treatment cessation might alleviate toxicity without substantially
compromising efficacy in patients with cancer. We aimed to determine if a tyrosine kinase …

Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell …

…, T Jones, G Emlyn, P Huey, A Mullard - Journal of clinical …, 2023 - jcp.bmj.com
Aims Somatic genetic testing in non-squamous, non-small cell lung carcinoma (NSCLC)
patients is required to highlight subgroups eligible for a number of novel oncological therapies. …

[HTML][HTML] Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and …

…, M Richardson, R Dickson, A Mullard… - Health Technology …, 2015 - europepmc.org
Background Lung cancer is the second most diagnosed cancer in the UK. Over 70% of lung
cancers are non-small cell lung cancers (NSCLCs). Patients with stage III or IV NSCLC may …

[HTML][HTML] Checklists for complications during systemic cancer treatment shared by patients, friends, and health care professionals: prospective interventional cohort …

…, V Wakefield, P Innominato, A Mullard… - JMIR mHealth and …, 2020 - mhealth.jmir.org
Background: Advances in cancer management have been associated with an increased
incidence of emergency presentations with disease-or treatment-related complications. …

Intractable malignant ascites: An alternative management option

AP Mullard, JM Bishop, M Jibani - Journal of Palliative Medicine, 2011 - liebertpub.com
Background: Recurrent malignant ascites is a common management problem in oncology
and palliative care. Discussion: Here, we describe a case of malignant ascites managed by …

[HTML][HTML] Venous thromboembolism in malignancy

A Mullard, H Innes - Clinical medicine, 2014 - ncbi.nlm.nih.gov
Venous thromboembolism (VTE) is an important cause of morbidity and mortality in patients
with cancer. It occurs in up to 20% of patients with an overt malignancy and is the second …

[PDF][PDF] Evaluating process and effectiveness of a low-intensity CBT intervention for women with gynaecological cancer (the EPELIT Trial)

…, C MacDonald-Smith, A Mullard… - AMRC Open …, 2021 - … .s3.eu-west-1.amazonaws.com
Background: Improving survival from gynaecological cancers is creating an increasing clinical
challenge for long-term distress management. Psychologist-led interventions for cancer …

Correction: checklists for complications during systemic cancer treatment shared by patients, friends, and health care professionals: prospective interventional cohort …

…, V Wakefield, P Innominato, A Mullard… - JMIR mHealth and …, 2020 - mhealth.jmir.org
Author Derick Gwyn Murdoch was incorrectly listed with given names “Derick Gwyn” and
surname “Murdoch”, and listed in the article citation as “Murdoch DG.” This was incorrect and …

[PDF][PDF] Evaluating process and effectiveness of a low-intensity CBT intervention for women with gynaecological cancer (th e EPELIT Trial)[version 1; peer review …

…, RJ Flynn, R Pendrous, C MacDonald-Smith, A Mullard… - 2021 - scholar.archive.org
Background: Improving survival from gynaecological cancers is creating an increasing clinical
challenge for long-term distress management. Psychologist-led interventions for cancer …

Radical hypofractionated radiotherapy for the treatment of non-small-cell lung cancer using 52· 5–55 Gy in 20 fractions: the North Wales Cancer Centre experience

N Ghosal, AP Mullard, NM Chowdhury… - … of Radiotherapy in …, 2015 - cambridge.org
BackgroundRadical hypofractionated thoracic radiotherapy is the most commonly used
radiotherapy schedule for inoperable non-small-cell lung cancer (NSCLC) in the United Kingdom…